Praxis Precision Medicines, Inc. PRAX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific expenses by Product | ||||||
| Elsunersen | $9.27M+35.7% | $6.83M+41.0% | $4.85M+61.2% | $3.01M+26.6% | $2.38M+11.2% | |
| Other early stage assets | $10.16M+26.6% | $8.02M+13.6% | $7.06M+38.5% | $5.09M+5.7% | $4.82M+4.0% | |
| Relutrigine | $53.43M+16.3% | $45.95M+36.7% | $33.61M+68.8% | $19.91M+87.0% | $10.64M+69.7% | |
| Ulixacaltamide | $58.8M-7.0% | $63.21M-20.5% | $79.55M-9.5% | $87.89M+7.8% | $81.55M+17.9% | |
| Vormatrigine | $80.82M+9.1% | $74.06M+19.9% | $61.74M+30.1% | $47.46M+51.3% | $31.36M+70.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Praxis Precision Medicines, Inc. break its business down?
- Praxis Precision Medicines, Inc. (PRAX) reports program-specific expenses by product across 5 parts — Elsunersen, Other early stage assets, Relutrigine, Ulixacaltamide and Vormatrigine. Each is extracted from the segment footnotes and tracked over time.
- Where does Praxis Precision Medicines, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Praxis Precision Medicines, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.